MedTrace Logo

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

NCT04508725 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Conditions

Interventions

DIAGNOSTIC_TEST

Doppler Ultrasound

Power Doppler measurements will be made

DEVICE

SIEMENS S3000 and Verasonics Vantage 256

Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics

DRUG

Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)

Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).

DRUG

Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

Sponsors & Collaborators

Principal Investigators

  • Alice C Fan, MD · Stanford University

  • Jeremy Dahl, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-05
Primary Completion
2023-11-30
Completion
2023-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04508725 on ClinicalTrials.gov